Journal article
CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response
Current opinion in oncology, Vol.15(6), pp.440-445
11/2003
DOI: 10.1097/00001622-200311000-00006
PMID: 14624226
Abstract
PURPOSE OF REVIEWCancer treatment is entering an era of targeted approaches. One such approach is use of the immune system to recognize and eliminate malignant cells. Synthetic CpG oligonucleotides (CpG DNA) are a relatively new class of agents that have the ability to stimulate a potent, orchestrated tumor-specific immune response. This review provides an overview of the immunologic effects of CpG DNA and summarizes the results of preclinical investigations that have led to ongoing development of CpG DNA as a component of clinical cancer immunotherapy.
RECENT FINDINGSNew studies demonstrate that at least three classes of CpG DNA sequences exist, each with different physical characteristics and biologic effects. Preliminary studies in several animal models of cancer suggest that CpG DNA have the ability to induce tumor regression by activating innate immunity, enhancing antibody dependent cellular cytotoxicity, and serving as potent vaccine adjuvants that elicit a specific, protective immune response.
SUMMARYAnimal models suggest that CpG DNA may have many uses in cancer immunotherapy. Early clinical trials suggest that CpG DNA can be administered safely to humans, and studies are ongoing to understand how these agents may play a role in cancer immunotherapy.
Details
- Title: Subtitle
- CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response
- Creators
- James Wooldridge - University of IowaGeorge Weiner
- Resource Type
- Journal article
- Publication Details
- Current opinion in oncology, Vol.15(6), pp.440-445
- Publisher
- Lippincott Williams & Wilkins, Inc
- DOI
- 10.1097/00001622-200311000-00006
- PMID
- 14624226
- ISSN
- 1040-8746
- eISSN
- 1531-703X
- Language
- English
- Date published
- 11/2003
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
- Record Identifier
- 9984359579402771
Metrics
7 Record Views